| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 192.10 | 16.1% | 9.3% |
| Total Income | 192.10 | 16.1% | 9.3% |
| Expenditure | 252.33 | 64.6% | 87.1% |
| PBT | -57.95 | 447.6% | 228.9% |
| Net Profit | -45.12 | 300.5% | 217.2% |
| OPM | -31.35% | 38.69pp | 54.60pp |
| NPM | -23.49% | 37.08pp | 45.40pp |
| EPS | -0.80 | 300.0% | 214.3% |
Supernus Reports Q3 2025 Revenue Up 9% to $192.1 Million
04 May 2026 · 4 May, 8:11 am
Summary
Supernus Pharmaceuticals, Inc. announced financial results for the third quarter of 2025. Total revenues increased by 9% to $192.1 million compared to the same period in 2024. The combined revenues of the company's four growth products increased 52% to $149.2 million. The company is increasing its full year 2025 revenue guidance and updating its full year 2025 operating earnings (loss) guidance to reflect strong performance in the first nine months of 2025. The company completed the acquisition of Sage Therapeutics, Inc. on July 31, 2025.
Key Highlights
- 1
Combined revenues of the company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024.
- 2
Total revenues were $192.1 million in the third quarter of 2025, a 9% increase compared to the same period in 2024.
- 3
Net sales of Qelbree increased 31% to $81.4 million in the third quarter of 2025, compared to the same period in 2024.
- 4
Net sales of GOCOVRI increased 15% to $40.8 million in the third quarter of 2025, compared to the same period in 2024.
- 5
ONAPGO generated net product sales of $6.8 million in its first full quarter following U.S. commercial launch in April 2025.
- 6
Collaboration revenue from ZURZUVAE was $20.2 million in the third quarter of 2025.
- 7
The company is increasing full year 2025 revenue guidance and updating full year 2025 operating earnings (loss) guidance to reflect strong performance in the first nine months of 2025.
Management Comments
Jack Khattar
Our strong operating results continued into the third quarter of 2025, reflecting continued momentum from Qelbree and GOCOVRI, collaboration revenue from ZURZUVAE, and an encouraging start to the launch of ONAPGO. Our focus for the remainder of the year and into 2026 will be on the performance of our four growth products and the high-level operating performance across the business to deliver sustained growth and long-term value for shareholders.
Informational and educational content only. Not investment advice.